Related Experiment Video
Updated: Aug 8, 2026
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
An enzyme-linked immunosorbent assay for complement regulatory proteins and membrane-bound immunoglobulins on intact
D R Jones1, R J Thompson, S A Rao
1Department of Immunology, University Hospital, Queen's Medical Centre, Nottingham, UK.
Insights
A new ELISA technique reveals potential roles for decay accelerating factor (DAF) in immune complex transport in autoimmune disorders like autoimmune hemolytic anemia (AHA) and systemic lupus erythematosus (SLE). This method identified specific complement receptor 1 (CR1) expression patterns in patient subsets.
Area of Science:
- Immunology
- Hematology
- Biochemistry
Background:
- Autoimmune disorders involve immune system dysregulation affecting red blood cells (RBCs).
- Immune complex transport is crucial in autoimmune diseases, but the precise mechanisms involving RBC-bound molecules are not fully understood.
- Complement regulatory proteins play a role in modulating immune responses.
Purpose of the Study:
- To develop and apply an ELISA technique for examining RBC-bound molecules in autoimmune disorders.
- To investigate the involvement of complement regulatory proteins, specifically decay accelerating factor (DAF), in immune complex transport.
- To identify patterns of complement receptor 1 (CR1) expression on RBCs in patients with autoimmune hemolytic anemia (AHA) and systemic lupus erythematosus (SLE).
Main Methods:
- Development of an Enzyme-Linked Immunosorbent Assay (ELISA) technique.
- Analysis of RBC-bound molecules using the developed ELISA.
- Investigation of immune complex transport mechanisms.
- Assessment of complement regulatory protein function.
- Characterization of complement receptor 1 (CR1) expression patterns on RBCs using specific monoclonal antibodies (E11 and C3RTo5).
Main Results:
- The developed ELISA technique successfully examined RBC-bound molecules in autoimmune disorders.
- Evidence suggests that decay accelerating factor (DAF) may be involved in immune complex transport.
- A subset of patients with autoimmune hemolytic anemia (AHA) and systemic lupus erythematosus (SLE) exhibited distinct patterns of CR1 expression.
- In these patients, CR1 identified by monoclonal antibody E11 was low or absent, while CR1 identified by DAKO monoclonal antibody (C3RTo5) remained at normal levels.
Conclusions:
- The novel ELISA technique is effective for studying RBC-bound molecules in autoimmune conditions.
- Decay accelerating factor (DAF) is implicated in the process of immune complex transport.
- Specific CR1 expression patterns on RBCs can identify patient subsets within AHA and SLE, potentially indicating different disease mechanisms or responses.
Abstract:
We have developed an ELISA technique to examine RBC-bound molecules in autoimmune disorders. In particular, the technique has enabled us to investigate the role of some complement regulatory proteins in immune complex transport and to suggest that decay accelerating factor (DAF) may be involved in this process. In both autoimmune haemolytic anaemia (AHA) and systemic lupus erythematosus (SLE) a sub-set of individuals was identified, on the basis of patterns of complement receptor 1 (CR1) expression on RBC. In these patients, CR1 identified using the monoclonal antibody E11 was low or absent whereas CR1 identified using a DAKO monoclonal antibody (C3RTo5) was present at normal levels.
